These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 32297439)
1. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439 [TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391 [TBL] [Abstract][Full Text] [Related]
3. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276 [TBL] [Abstract][Full Text] [Related]
4. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380 [TBL] [Abstract][Full Text] [Related]
5. Prevalence and Spectrum of Antonarakis ES; Zhang N; Saha J; Nevalaita L; Ikonen T; Tsai LJ; Garratt C; Fizazi K JCO Precis Oncol; 2024 May; 8():e2300330. PubMed ID: 38781544 [TBL] [Abstract][Full Text] [Related]
6. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma. Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410 [TBL] [Abstract][Full Text] [Related]
7. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493 [TBL] [Abstract][Full Text] [Related]
8. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703 [TBL] [Abstract][Full Text] [Related]
9. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812 [TBL] [Abstract][Full Text] [Related]
10. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
11. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615 [TBL] [Abstract][Full Text] [Related]
12. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422 [TBL] [Abstract][Full Text] [Related]
13. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695 [TBL] [Abstract][Full Text] [Related]
14. Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer. Dincman TA; Karam JAQ; Giordano A; Li H; Drusbosky LM; Gourdin TS; Howe PH; Lilly MB Front Oncol; 2023; 13():1202277. PubMed ID: 38450313 [TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634 [TBL] [Abstract][Full Text] [Related]
16. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366 [TBL] [Abstract][Full Text] [Related]
18. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750 [TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. Moses M; Koksal U; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Sartor AO; Barata P Oncotarget; 2020 Jan; 11(1):15-21. PubMed ID: 32002120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]